-
Pfizer's Prevnar 13 Meets All Study Endpoints in Two Phase III Trials (PFE)
Monday, May 9, 2011 - 8:03am | 21Pfizer's Prevnar 13 Meets All Study Endpoints in Two Phase III Trials (NYSE: PFE)
-
A Peek Into The Market Before The Trading Starts
Monday, May 9, 2011 - 7:45am | 360Pre-open movers US stock futures are higher this morning. Futures on the Dow Jones Industrial Average gained 59 points to 12,628.00 and futures on the S&P 500 stock index rose 6.30 points to 1,341.30. Nasdaq 100 futures surged 16.50 points to 2,390.00. A Peek Into Global Markets Most Asian...
-
Obagi Medical Stops Shipping Due to Texas Attorney General Allegations -Bloomberg (OMPI)
Monday, May 9, 2011 - 7:39am | 23Bloomberg reports that Obagi (NASDAQ: OMPI) medical stops shipping due to Texas attorney general allegations.
-
Updates- LinkedIn IPO, Oil, Yuan, HTZ, DTG, AES, TSN, BID, ATVI, SRE, PETS, RST, SYY, CLR…
Monday, May 9, 2011 - 7:26am | 1907It looks like, Oil prices could drop as low as $90 a barrel later this month as the global economy slows and unrest in the Middle East eventually fades. Crude oil for June delivery rose $2.91 to $100.09 a barrel. Gold for June delivery rose $14.80 to $1,506.50 an ounce, and silver for July...
-
Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study (INHX, PFE)
Monday, May 9, 2011 - 7:22am | 135Inhibitex (Nasdaq: INHX), announced today that Pfizer Inc. (NYSE: PFE) presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine (SA3Ag) at the 21^st...
-
Goldman Sachs Comments On Warner Chilcott Following Recent Earnings Report
Monday, May 9, 2011 - 7:22am | 173Warner Chilcott (NASDAQ: WCRX) shares responded well Friday to strong top and bottom line numbers for the first quarter. Not surprisingly, business development remains a key theme and, potential driver of meaningful upside on the right deal and likely to continue to be a primary investor focus over...
-
Goldman Sachs Comments On Warner Chilcott Following Recent Earnings Report
Monday, May 9, 2011 - 7:22am | 173Warner Chilcott (NASDAQ: WCRX) shares responded well Friday to strong top and bottom line numbers for the first quarter. Not surprisingly, business development remains a key theme and, potential driver of meaningful upside on the right deal and likely to continue to be a primary investor focus over...
-
Salix Pharmaceuticals Receives Lawsuit from Napo Pharmaceuticals
Monday, May 9, 2011 - 7:04am | 95Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) announced today that Napo Pharmaceuticals, Inc. has filed a lawsuit against Salix Pharmaceuticals alleging that the Company has breached its commitments under the Collaboration Agreement between Napo and Salix concerning the development of crofelemer....
-
Calls Purchased on ViroPharma Incorporated (VPHM)
Friday, May 6, 2011 - 1:58pm | 125Shares of ViroPharma Incorporated (NASDAQ: VPHM) are higher on the session by 2.16%, currently trading at $19.03. The stock has been moving largely higher over the past six months and is currently trading above the 200-day moving average. Options traders are buying calls on the name today. A short...
-
Options Brief: Warner Chilcott PLC (WCRX)
Friday, May 6, 2011 - 12:04pm | 79Shares of Warner Chilcott PLC (NASDAQ: WCRX) are higher on the session by 5.90%, trading at $23.50. Overall put volume is now running at 6.38x the daily average, with 12% of all puts traded being purchases on the offer. 2,860 contracts have traded on the session so far. Warner Chilcott PLC,...
-
Cash in on George Clooney's 50th Birthday
Friday, May 6, 2011 - 11:50am | 556George Clooney turns 50 on Friday, reminding men everywhere that it is possible to be desired by women across the globe, as long as you are amazingly talented, incredibly sexy, and wealthier than most royal families. With that in mind, Benzinga looks at five talented, wealthy, and — dare we say —...
-
UPDATE: Abbott Receives FDA Approval to Expand Use of the RX ACCULINK Carotid Stent System to Patients at Standard Surgical Risk
Friday, May 6, 2011 - 11:38am | 99Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy. RX ACCULINK was previously indicated for...
-
Synthes Sued in Delaware by Shareholder Over J&J Purchase -Bloomberg (JNJ)
Friday, May 6, 2011 - 11:28am | 20Synthes sued in Delaware by shareholder over J&J (NYSE: JNJ) Purchase.
-
UPDATE: FDA Approves New Treatment for Rare Type of Pancreatic Cancer (NVS)
Friday, May 6, 2011 - 10:00am | 108Afinitor is also approved to treat patients with kidney cancer (advanced renal cell carcinoma) after they fail treatment with Sutent (sunitinib) or Nexavar (sorafenib); and patients with subependymal giant cell astrocytoma (a type of brain cancer) associated with tuberous sclerosis (a disease that...
-
UPDATE: FDA Approves New Treatment for Rare Type of Pancreatic Cancer (PFE, MRK, GSK)
Friday, May 6, 2011 - 9:58am | 38Related stocks include: Pfizer (NYSE: PFE), Merck (NYSE: MRK), Glaxo Smith Kline (NYSE: GSK)